ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
'Umbrella' Valve Provides A Potential Alternative To Lung Surgery
A new umbrella-like valve may
help patients with emphysema breathe easier and may ultimately provide a
noninvasive alternative to lung reduction surgery. In a new study presented
at CHEST 2006, the 72nd annual international scientific assembly of the
American College of Chest Physicians (ACCP), the IBV(TM) Valve, a
nonsurgical, investigational device, was shown to be safe and effective for
patients with emphysema.
Emphysema -- a subtype of chronic obstructive pulmonary disease (COPD)
-- is a progressive and debilitating lung disorder, characterized by
irreversible airflow obstruction. Current management for emphysema includes
medication and/or supplemental oxygen, pulmonary rehabilitation, and, in
rare cases, lung volume reduction surgery (LVRS) to remove the most
diseased portions of the lung.
"The IBV(TM) Valve is similar in concept to LVRS in that it aims to
make the lungs work more efficiently, thereby decreasing shortness of
breath," said the study's lead author Daniel H. Sterman, MD, FCCP,
University of Pennsylvania Medical Center, Philadelphia, PA. "Unlike lung
reduction surgery, valve treatment has fewer complications and a shorter
hospital stay. For example, most valve-treated patients have a one-night
observational hospital stay while surgical patients average a week or more
in the hospital." The one- way IBV(TM) Valve limits ventilation in diseased
areas of the lungs and redirects ventilation to the remaining healthier
portions of the lung while allowing for normal clearance of secretions.
In a multicenter preliminary pilot study, Dr. Sterman and researchers
from the Cleveland Clinic Foundation, Cleveland, OH, University of
Washington, Seattle, WA, and six additional US medical centers examined the
safety and effectiveness of the IBV(TM) Valve on patients with severe
upper-lobe emphysema. Over a 27-month period, 520 valves were implanted in
75 patients across the nine medical centers. The valves were implanted in
the upper lobes of the lung using flexible bronchoscopy, with an average of
6 to 7 valves implanted per patient. Researchers used quantitative software
and multidetector CT scans to measure the physical effects of the valves
and the St. George Respiratory Questionnaire (SGRQ) to assess how patients
felt after treatment.
Of the patients who received valve treatment, 46 patients (group A) had
reduced complications and retained efficacy compared with the remaining
patients (group B). In responding patients, valve treatment transferred an
average of 20 percent ventilation and perfusion to healthier regions of the
lung. Two thirds of patients in group A also had a 4-point or more SGRQ
improvement at 6 months and showed significant improvements in oxygen use
and dlco. Compared with patients in group B, patients in group A were less
than 75 years old, did not have lingular treatment, and had fewer lung
segments treated. The 90-day serious complications were one bronchospasm
and one COPD flare in the A group and two bronchospasm and one death with
pneumothorax in group B.
"Patients responding to valve treatment may now be able to do simple,
everyday activities, such as bathe or shower independently, walk around the
house without stopping, talk without trouble breathing, and can go out for
shopping or entertainment," said study coauthor Atul C. Mehta, MD, FCCP,
Cleveland Clinic Foundation. "Although valve treatment is still
investigational, it may offer an alternative treatment for patients with
emphysema who are not good candidates for LVRS." Researchers stress that
valve treatment is not yet approved by the US Food and Drug Administration
and is only available as part of a research trial that is currently
sponsored by the developer of the IBV(TM) Valve, Spiration, Inc.
"Although there is no cure for emphysema, proper treatment can improve
a patient's exercise capacity, overall quality of life, and may result in
longer survival," said Mark J. Rosen, MD, FCCP, President of the American
College of Chest Physicians. "Valve treatment may represent a valuable
option for the palliative treatment of patients with emphysema."
CHEST 2006 is the 72nd annual international scientific assembly of the
American College of Chest Physicians, held October 21-26 in Salt Lake City,
UT. ACCP represents 16,500 members who provide clinical respiratory,
critical care, sleep, and cardiothoracic patient care in the United States
and throughout the world. The ACCP's mission is to promote the prevention
and treatment of diseases of the chest through leadership, education,
research, and communication. For more information about the ACCP, please
visit the ACCP Web site at http://www.chestnet.org.
American College of Chest Physicians
http://www.chestnet.org
"Umbrella" Valve oferã o alternativã la Lung Potential de Chirurgie - 'Umbrella' Valve Provides A Potential Alternative To Lung Surgery - articole medicale engleza - startsanatate